Aqemia SAS

About Aqemia SAS

Aqemia is a Paris-based drug-discovery company founded in 2019 that combines deep physics algorithms with generative AI to predict the potency and safety of drug candidates. Its platform screens billions of small molecules in silico, prioritizing candidates for synthesis and experimental validation. The company partners with pharmaceutical firms and biotechs to accelerate hit-to-lead and lead-optimization programs across oncology, immunology, and neurology. Aqemia’s pipeline includes internal assets and collaboration projects, aiming to shorten development timelines and reduce early-stage R&D costs while maintaining high success rates in identifying novel therapeutic candidates.